ERBB2 and non-small cell lung carcinoma: The ZENITH20-2 study reported a median PFS of 5.5 months and an improved ORR of 35.1% in patients with NSCLC harboring HER2 exon 20 insertions treated with the novel pan-ErbB TKI poziotinib [31].